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• Meletonln, Pineal HormoneWlth Antloxldant a 
Property, Protects Against Adrlsmycln 
Cardlomyopsthy In Rats 
I. Morlshlmn, Y, Tekt, K. Okumura, T. ito. Internal Medicine II, Nagoy,'t 
Unlversl~ Nttgoy,'t, Japan 
B~tckgmund: The clinical use of adrlamynin (ADR) is limited by its cardlofox. 
ICily In which free radicals and lipid peroxldaflon m~y be involved, Melatonln 
(MEL) has gained Increasing interest aa a strong antloxldsnt. Accordingly, 
the protective effects of MEL ~galnst ADR cardiomyopathy was evaluated. 
Method: Male Sprague.Dawley r~t~ were divided Into 4 gro~,=p~ as follows: 
ADR (ADR treated, cumulative dose 15 mg/kg bw, Ip, for 2 weeks), MEL 
(MEL treated, cumulative dose 84 mglkg bw, Ip), MEL + ADR (MEL + ADR 
treated), and CeNT (control), After 3 weeks of post treatment observation. 
their cardiac perferman0e w{la assessed, and th(~lr lloarts worn used to 
study myocardial lipid pcroxtd~tion by measuring thiobarblturtc acid reactive 
~ubstance (TBARS) along wttl~ ultrastructuro, 
Results: MEL rovemea the ADR induced cl~nnflo~ in myocardial ultra- 
structure aa well as parameters hown below, 
CeNT ADR MEL MEL + AOR 
HW/E]W ratio 2,03 L 005 2,30 ~ 0,05" 261 t: 0,06 2,71 L 0,05 
A@clt@s (mr) 0 31,7 ~ 03" 0 3;~ ~ 22 
~9P (mmH~]) 124.4 t 2.6 t07.4 L 41' 1~63 t 3.9 124.1 t 32 
FS (%) 508 t 1,t 30.4 t: ~3"  53,4 ! 1 6 500, :* 1 1 
Mortrdity t%) 0 23" 0 0 
TBARS(nmol/gho~rt) 51 3 t 1 1 638 t ~;~" 45 9 ~ 1 6 51 4 t 20 
Datt~ are mann ~ SEM. "p  • 001, "p , 00S vs ~11 oth~tr groups HW/BW: Hnnrt 
woighUbody woIght, SaP: Systolic blood Pro,~sUro, FS: Fr,~cti~n~t shortening 
Conclusion: MEL may be highly effective In protecting against ADR car- 
diomyopathy by pmventin 9 lipid parexidation. 
• Tumor Necrosis Factor-~ Induces Contract i le 
Dysfunction In Conjunct ion With Nitric Oxide 
Production In Conscious Dogs 
D.R, Murray, B. Chandrasekar, G,L, Freeman. Medicine/Cardiology The 
Univemit), at Texas Health Science Center, and ALMMVH, Sat) Antonio, TX 
7'8284.7874, USA 
Tumor necrosis lacier (TNF).(Y promotes elaboration of the inducible iso- 
torm of NO synlhase fiNeS); however, the relationship between subsequent 
NO prodactton and the development of contractile dysfunction in vi~,., is not 
known. Accordingly, six chronically instrumented, conscious dogs pretreated 
with propranolol (2 mg/kg) and atropine (2 rag) were studied before and 
after 1 hour infusion of TNF.~, (40 ;~g/kg). LV contractility was determined 
by end-systolic elastanco, Eos 1,ram Hgtml). and plasma nitrite + nitrate 
levels (NO~ +NO~; t~M) by vanadium roauctton, Dogs wore killed 24 hour 
after TNF-t~ or saline; hearts were frozen and assessed for iNOS protein 
levels (Western blotting), iNOS enzyme activity (conversion of ~H-arginine 
to 3H-citru!line in the presence of EGTA+EDTA), localization of iNOS (im- 
munohistochemistry, IHC). and NF-~ B. a transcription factor involved in the 
upregulation of iNOS (etectr,~phoretiC mobility shift assay). In TNF-(r treated 
dogs. we observed a 4-fold increase in NF-,B levels, a 3-laid increase in 
myocardial iNOS protein, and an 18*fold increase in enzymatic activity (P ... 
0,001 for each). IHC localized iNOS predominantly to vascular endothelium 
and smooth muscle and less intensely to cardiomyocytes. 
Pm-TNF-~v 1 h posl 7 h post 24 h pc'c~ 
Ees 5.4 ~ 04 79 ~ 1 4' 5.2 ~ 05 32 ~ 04' 
NO;~ +NO;) 17.6 ± ~.5 14.7 ± 1 4 18.6 ~. 1.8 38.5 t 64' 
'P ~ 0 05Vscorrespondingpre-TNF-, 
We Conclude: TNF-¢t administration upregulates functionally active iNOS 
in the heart, possibly through activation of NF., B, Increased Plasma metabo- 
tiles of NO stror, gly correlate with ;a viva cardiac depression after TNF-~. 
• Positive Inotroplc Effect of Bradyklnln: Role of 
Cardiac Endothellum, Nitric Oxide, 
Prostaglandlne and Endothelln 
P, Mohan, D,L, Brutsaort, S,U, Sys, Untverstty of Antwerp, Antwerp, Belgium 
Background: Bradyklnln (Brad) causes endethelium-dependent vascular 
smooth muscle relaxation and may explain some of the beneficial cardiac 
effects of angtotensln converting enzyme inhibitor therapy, grad recoptom 
are also present on cardiomyocytes, However, the Inotmplc effect of Brad 
on myocardlum, In particular role of endocardlat endothellum fEE), media. 
tom released by EE.nltrlc oxide (NO), pmstnglandlns (PG) ~nd endothnlln, 
rind Interaction with concomitant/hadrenerglc stimulation have not been 
investigated, 
Methods: Wc examined myocardial effects of Brad (10 °M to 10 s M) in 
isolated Cat papillary muscles (Krobs-Rlnger 1,25 mM Ca" .  35oC, enalsprilat: 
5 x 10 ~ M, nfenotol: 2 x 10 ~ M) before (+EE: n = 7) and aftQr selective 
damage of EE (-EE: n = 7: ls immersion in Trlton.X, 0,5%), To investigate 
role of NO, PG sad ondotheltn, Br~d was also added in subgroups of *EE 
muscles incubated with L-NA (3 ~. 10 ~ M, n ~ 8), indomethacin (INDO: 10 ~ 
M, n ..= 8) or 90123 (10 " M, n = 7) respectively, 
Results: (mean t SE, A% baseline) In .EE, Brad induceq an dose. 
dcpendent increase in peak aotivo tension (AT'. 10 ~ M =. 93 :t: 3,1) with no 
change in time to hall relaxation (0.7 t 1 4), This response was blocked by 
the brndykinin recoptc~r antagonist (HOE 140; 10 7 M, n = 3) and was absent 
in .EE, The inotropto response to grad was not inhibited by LNA, INDO or 
BQf23 alone but wa~, inhibited by LNA + INDO (Brad: 10 ~ M; AT = 1.0 -,: 
1.6). Isepretoronol 1,3 . 10 " M).inducod increase tn AT 1,14,4 , 2.0) was 
abollshod by I~md (10 s M) (0.2 t 4.2), which was not modified by LNA + 
tNDO (Q,3 :t~ 4.3), 
Conclusion: Brad induced a cardiac endothalium-dependent positive in- 
otmplc myocardial effect with no effect on relaxation, which was mediated 
by both NO and PG. Brad abolished the effect of concomitant/~.adrenergic 
stimulation, independent of NO and PG. 
• Atrial Natdumtlc Peptlde Decreases Contracti l ity 
end Intracellular pH In Adult Ventrlculsr Myocytes 
M. Tajimo. J, Badunok. BH. Lor~tl. B. Israel. Deaconess Medical Center 
and Harvard Medical School Boston. MA. USA 
Atdal natnuretic peptide (ANP)-cGMP signaling modifies cardiac function by 
natnuresis and vasodilaUon but inotropic effects are controverSial. We stud- 
ied effects of ANP on cell shortening and infracellular signaling in HEPES- 
buffered adult ventricular mt myocytes (n = 26) paced at 0,5 Hz. At baseline 
(B). fractional cell shortening (FS) was 7.9 i 0.2% and intracellular pH (pHi, 
SNARF-1) was 6.92 z~- 0.05. ANP caused a dose-dependent depression el 
contractility (Fig. 1 ). associated with intraeellular acidilicaticJn (Fig. 2). In cells 
loaded with Flue-3 ~, ~ = 5). ANP caused no change in systolic [Ca `~" ]L 
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Summary., ANP directly depresses contractility via intracellular acidilica- 
lion and decreases myofilament [Ca ~*] sensitivity. Similar to negative in- 
otropi~; action of nitric oxide, this may be related to cGMP-mediated disabling 
of forward Na*-H" exchange. 
• Pharmacoklnetlcs of  Agent  Distr ibution From the 
Perlcardial Space: Effects of  Agent  Size and 
Validation of a Mathematical Model for Epicardial 
Penetration 
S,H. Baek. t r,-F. Stall. A. Szabo, LK. Keefer, J. Hrabie, K.L, March. indiana 
University Medical Center, Indianapolis. IN. National Institute of Health. 
Bethesda and Frederick. MD. USA 
Recent data have demonstrated reduction of restenosis in the porcine mod,~l 
by intrapericardial delivery of diazeniumdiolated albumin (NONO-AIb). The 
bioactivity of intrapericardial agents will be importantly modulated by their 
residence time as well as penetration into epicardial tissue. We thus evalu- 
ated the dependence of residence halt-life (RHL) on molecular weight (MW) 
JACC February I¢)g,~ ABSTRACTf~, P(~ler 1(tgA 
of agents, and developed and tested a reaction-diffusien model for myocar. 
dial penetration from the pericardial space. TM I.LysyHysine (LL), MW 420 D; 
~3~ I-NONO-AIb, MW 73 kD; and ~"~Tc.macreaggregated albumin (MAA), 30 
t~m diameter were delivered into the porcine pericardial space (n = 10) by a 
transmyocardiel route using a helix-needle (;atheter. Washout was assessed 
over "/2 h by serial Sctntigrsphy to dofine agent loss from the region of inter. 
est. Eptcardist-endocardtal concentration gradients (n = 5) established ;t h 
after agent delivery were assessed by measuring count rates of myocardial 
tissue series obtained by cryosectioning tangential to the eplcardiat sumacs, 
A maltmmatical model was tk~voloped based on a maction-diflusion ~luation 
~s~rlblng agent transfer into myocaKlium as a function of interstitial dlflu. 
sign, transcapi!ta, rywashout, penetration depth, and time, RHL was 98 ± 26 
h for MAA, 22 ~ 4 h for NONO-AIb, and 4,6 ± 0,5 h tor LL Sharp transmural 
concentration gradients were found for LL, with a penetration half.depth of 
~,5 ~t" 0.1 ram; these profiles were closely fit by our mathematical model [r 
0,95). In conclusion, physica! size el agents strongly influences intrapencar, 
dial residen(:e time; and transmural concentration gradients am steep, and 
well.modeled in terms of diftu~ion ~nd washout. These pharmacokinetic an~ 
tissue penetration ch~racteristtco will help to define appropriate agents and 
sutt~bl~ targets for intrapencardiat therapy. 
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~ Long-term Survival In Patients With Primary 
Syslemi¢ Amyloidosls Wlth Biopsy-proven 
Cardiac Involvement 
M. Grogan, MA. Gertz, RA. Kyle, J.B Seward. A.J. Taiik. Mayo Medical 
Center, Rochester, MN, USA 
Background: Prognosis in primary systemic areyloidosis with cardiac involve- 
ment is poor with a reported median survwal ot 5 months. The purpose of 
this study was to determine the frequency ot long-term survival (~5 yrS) ~n 
patients (pts) with pnmary systemic amyfoidesis with biopsy proven cardiac 
involvement. 
Methods: A review of all patients w;th i~nmary systemic amylo~des=s w=th 
biopsy proven cardiac involvement was performed. 
Results: One-hundred and fifty-tour pts with primary systemic amyloidosis 
with a positive cardiac (153 endomyocardial. I pencardial) biopsy for amyloid 
infiltration were seen from 1965 to 1997. Ten pts (~,o) were found to have 
long-term survival, with a median o! 138 months (range 76-181 ). Seven pts 
su~ved ~ 10 yrs and 6 of the 10 pts were alive at last follow up. All pts with 
long-term survival received chemotherapy, Median sunnval ot the remam=ng 
144 pts was 6 months. Initial EF was significantly higher (55 x 12 vs 47 
14%, p = . 0.001) and mean mitral deceleration time was longer (196 
7t vs 166 ± 45 msec, p =.  0.001) in pts wi|h ~5 yr survival. Initial septal 
thickness was not significantly different in those with - or -5 yr sunnval (15 
± 4 vs 16 ¢ 3 ram). 
Conclusion: Despite overall poor prognosis, long-term survival is possible 
=n treated pts with pnmary systemic amyloidosis and cardiac involvement 
including sunnval of -~10 years in 4% of pts. Higher inilial EF and longer 
mitral deceleration time were present in pts with tong-term survival. 
~ A  Comparative Echocardiographic Study of 
Primary, Familial and Secondary Amyloidosis 
I. Moyssakis. F. Triposkiadis, E. Chronakts, E. Kallieris, L. Rallidis, 
P. Nikoyannopoulos, M. Kyriakidis Department ot Cardiology, 
Hamreersmtth Hospital. London. UK: Department of Cardiology. Laiko 
Hospital, Athens. Greece 
Background: Amyloidosts (A) is characterized by the deposition of specific 
proteins in vanous organs. Currently recognized types include pnmary, sec- 
ondary and familial each of which may involve the heart. 
Material and Methcds: Lett ventncular (LV) morphology, LV diastolic and 
systolic function and right ventncular (RV) size and systolic function were 
echocardiographically (M-mode, 2D, pulsed and continuous Doppler) as- 
sessed in 28 patients with primary, 17 with familial and 11 with secondary 
A. To study disease progress in primary A, all patients underwent a repeat 
examination after a period of 15 ± 6 months. 
Results: Interventricular septal thickness (ram) was greater in primary 
or familial than in secondary A (14.1 ~_ 2.3 vs 13.9 ~- 1.98 vs 12.27 :~ 1 
respectively, p < 0.002) while LV posterior wall thickness (mm) was similar 
in the three groups (13.7 ± 2.4 vs 13.3 ~ 1.7 vs 12.18 ¢ 1.1. p = NS). LV 
fractional shortening (FS, %) was reduced in primary compared to familial 
(29,8 • 10.2 vs 36,2 ~: 65 vs p < 005. The fransmitlal flow velcc~'y (TFV) 
pattern was compatible with abnormal relaxatJ0n in most patients of the 3 
groul3s [primal: 16 (57%), familial: 1| (647%), secon~lry: 8 (72%), p = 
NS], RV thickening was preseht in 13 (46 4%) patients wdh primary. 6 (35%) 
with tt~mihat nd 1 (9%) w;th seconda~ A RV (fy~funclion was present in 
8 (28,6%), 2 (11.8%) and 0 patientS m=~pectn/ely. Rap#at exammat~0n Of
patients with primary A revealed detsherelion of LV systolic functc~n (FS 
236 ~ 8,8, p .~: 6.05 vs baseline) and increased froguency of LV reStrctK~ 
in TFV prolile (53.6% v~ 25% at baselino, p < 0.05). 
Conclusions: Primary amylotdosis causes more severe ¢~ia¢ involve. 
mont th~n the familial or secondary typQs, Progression of prima~ amytotdesis 
is rapid and t:haractarized by dets~nrelion el bolh left w~nt~ulaf (~asfol¢ 
and ~ystolic function. 
~ Echocltd iographl¢ Identlficatlon of CeRIia¢ 
AmyloldoSls I~tlents Capable of Undergoing 
Intenslv~ Treatment With Intravenous Melphelen 
Therapy 
LA  Mondes, JR, Reisinger, S.W. Dubrey, R Comenzo, E. Vosburgh, 
V. S~ncherawela, M. LaValloy, M. Skinner, R,H. Folk B~ston Medical 
Cent,,r. Boston. MA. USA 
Background: Pnmary amyloidests (AL) is a protein dopes;lion d;sease whch 
comes a poor prognosis, esl~'ciatly in patients (pts) with cardiac involvement, 
Intravenous melphalan (IViVt) toUowod by autologous tem cell transplanta. 
lion is an aggressive therapy which may produce disease remission and 
;reprove survwal. 
Methods and Res~jrts: To determine if pts with cardiac AL can be safely 
treated w~th this the, apy, we studied the echoca~lograms of 64 conse~utP/e 
pts undergoing IVM and measured seplal and POSterior wall (PW) thickness. 
LV end-diastolic diameter (LVEDD), LV mass, and tractional shortening (FS). 
Cardiac AL, defined as wall thickness > 1.1 cm, was present in 30 patients. 
After 6 months ot follow-up, 15 pts (50%) with cardiac amylord had died 
compa.'ed to 5 pts (15%) without cardiac disease (p = 0.006). Of me 30 pts 
with cardiac AL 9 died in the peri-therapy penod (~1 month) and 15 of the 
remaining 21 pts were alive at 6 months. 
Surwvat : n~nlh (n = 9) Surv'Nal :-1 month (n = 2 I) D value 
~eptum (cm) 1 43 ~ 022 1 30 • 0 13 0 07 
PW tom) 1 38~016 126 ~ ooa 001 
FS (%i 24 7 t- 8 S 3.3.6 +. 11 3 004 
There was no significant difference between the two groups wdh respect 
to LVEDD or LV mass. 
Conclusion: PTs w~th cardiac amylocd should not all be excluded from 
intensive IVM since careful echocardtographic evaluation peer to therapy 
can identify pts at high nsk for pen-treatment mortality. 
~ In(~idence of  Dilated Cardiomyopathy and 
Detection of  HIV in the Myoce~llal Cells In a Large 
Population of HIV.posltive Sub~::ts: A Long-term 
Clinical and Echocardiographlc FollOw-up 
G Barbaro, G. Di Lorenzo, B. Gnsorio t. G Barbarini "~. For the Gruppa 
Itah~ne per to Studio CaMiologlco dei pazienti affeffl da AIDS (G.I.S.CA]: 
Deparlment of Emergent, Medicine University "La Sapienza'. Rome, Italy: 
Division of Infectious Diseases, General Hospital. Foggia. Italy: 
Z Oepartment of Infectious Diseases, IRCCS Poticlinico S. MatteD. University 
of Pavia, Italy 
B~ckground: Human Immunodeticiency Virus (HIV) disease zs increasingly 
recognized as an important etiologic factor in Dilated Cardiomyopathy (DC). 
Aim of the study was to assess the incidence of echocarcliographically- 
diagnosed DC over time fn a large and selected population of HIV-positive 
subjects, correlabng the morphologic and functional parameters w~th clinical 
and virologic data. 
Method.?,: Nine hundred and fi~' two asymptomatic HIV*positive subject 
were long-term f011owod-up by clinical and echocardiographic examinations, 
which were pedormed, respectiveJy, every three and six months DC was 
defined as the presence of diffuse left ventncular hypokinesia (election frac- 
tion - 45%) and left ventncular dilatation (let ventdcular end--diastolic volume 
index >80 mVm2). The patients with echocardiographic diagnosis of DC un- 
derwent endomyocardial biopsy (EMB) for histolegic, immunohistol0gtc and 
virologic examination. 
Results: During the follow-up period (60 ± 5.3 months), echocardiographic 
diagnosis of DC was made in 76 patients (7.9%), with a mean incidence of 
1.2 new cases/month and 15.3 new cases/year. The relative risk for develop- 
ment of DC was greater i.n homosexuals patients, in those with a CD4+ cell 
count .:400/ram 3 and in those who received therapy with z~dovudine. All pa* 
tients with echocardiographie diagnosis of DC underwent EMB. Histological 
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